Cargando…
A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor
Psoriatic arthritis (PsA) is a unique inflammatory arthritis due to the fact that patients have to deal not only with pain but also with their skin appearance, which may have a detrimental effect on their everyday lives and psychology. Treating a patient with PsA, improving both the musculoskeletal...
Autores principales: | Pelechas, Eleftherios, Memi, Tereza, Voulgari, Paraskevi V., Drosos, Alexandros A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696296/ https://www.ncbi.nlm.nih.gov/pubmed/29022197 http://dx.doi.org/10.1007/s40744-017-0084-0 |
Ejemplares similares
-
Golimumab for Rheumatoid Arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019) -
Seronegative Erosive Arthritis Following SARS-CoV-2 Infection
por: Drosos, Alexandros A., et al.
Publicado: (2021) -
Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019) -
Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?
por: Drosos, Alexandros A., et al.
Publicado: (2019) -
Anti-Rheumatic Drugs May Ameliorate the Clinical Course and Outcome of COVID-19 In Rheumatoid Arthritis Patients
por: Pelechas, Eleftherios, et al.
Publicado: (2022)